Today it was reported that the CEO of Marinus (MRNS), Christopher Michael Cashman, exercised options to buy 31,662 MRNS shares at $1.04 a share, for a total transaction value of $32.93K.
This recent transaction increases Christopher Michael Cashman’s holding in the company by 13.21% to a total of $1.06 million. Following Christopher Michael Cashman’s last MRNS Buy transaction on January 30, 2019, the stock climbed by 0.7%.
See today’s analyst top recommended stocks >>
Currently, Marinus has an average volume of 1.39M.
Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $18.13, reflecting a 363.7% upside. Five different firms, including Cantor Fitzgerald and Jefferies, currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
